Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics Q3 EPS $(1.59) Beats $(1.68) Estimate
Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029
Eikon Therapeutics, Inc. (EIKN) Presents at JP Morgan Biotech Call Series Transcript
Eikon Therapeutics to Participate in Multiple Investor Conferences in November
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Eikon Therapeutics Files Submits Investigational New Drug Application To FDA To Evaluate EIK1006 To Treat Advanced Metastatic Prostate Cancer
Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Eikon Therapeutics to Participate in Investor Conferences in September 2026
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.